Business
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"\nQuantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nTriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink’s CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide.\n\n\nTriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom’s (sa)mRNA production platform, allowing customers to benefit from the industry’s leading capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases.\n\n\n\"Strengthening global health against infectious diseases requires strong industry partnerships,\" said Becky Buzzeo, Chief Commercial Officer at Maravai. \"We're excited for the Quantoom production platform to incorporate TriLink’s CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources.\"\n\n\nSince its debut in 2017, TriLink’s CleanCap capping technology has transformed the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines.\n\n\n“We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal,\" said José Castillo, CEO of Quantoom Biosciences. \"By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need.\"\n\n\nAbout TriLink BioTechnologies\n\n\nTriLink BioTechnologies,...